Spotlight Growth
No Result
View All Result
Saturday, August 13, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Biohaven Pharmaceuticals (NYSE: BHVN) Agrees to be Acquired by Pfizer (NYSE: PFE) for $11.6 Billion

by admin
May 10, 2022
in Bio/Med/Pharma
0
Pfizer NYSE PFE Biohaven NYSE BHVN Acquisition Spotlight Growth

Pfizer NYSE PFE Biohaven NYSE BHVN Acquisition Spotlight Growth

Biohaven Pharmaceuticals (NYSE: BHVN) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and commercialization of novel therapies to treat neurological and neuropsychiatric diseases. Shares of the biopharma company are soaring 70% through early trading on Tuesday, May 10, 2022. Over the past three months, Biohaven Pharmaceuticals has seen average daily volume of 678,450 shares. However, volume of 8.59 million shares or dollar volume of around $1.22 billion, has already exchanged hands through early trading.

Shares of Biohaven Pharmaceuticals are surging after the company announced that it has entered into a definitive agreement to be acquired by Pfizer (NYSE: PFE). Under the terms of the agreement, Pfizer will pay Biohaven common stock shareholders $148.50 per share in cash and half a share of the new publicly traded company that retains Biohaven’s non-CGRP pipeline compounds. In total, the transaction is valued at $11.6 billion. The transaction is estimated to close by early 2023.

Among the assets Pfizer will be acquiring is Biohaven’s NURTEC ODT treatment for migraines and preventative treatment for episodic migraines. NURTEC ODT is already approved for use in the European Union under the brand name VYDURA. Pfizer plans to continue the commercialization process of NURTEC ODT in the United States.

In addition, Pfizer will retain Biohaven’s Zavegepant drug candidate, which is an intranasal spray for treatment of migraine and also being developed as an oral soft gel for the prevention of chronic migraines. Pfizer will also hold onto a portfolio of five pre-clinical CGRP assets.

“Today’s announcement builds on our legacy of delivering breakthroughs for patients living with complex pain disorders and diseases that disproportionately impact women,” said Nick Lagunowich, Global President, Pfizer Internal Medicine. “NURTEC® ODT, which is already the #1 prescribed migraine medicine in its class in the United States, coupled with Biohaven’s CGRP pipeline, offers hope for patients suffering from migraine worldwide. We believe Pfizer is uniquely positioned to help the portfolio reach its full potential given our leading scale and capabilities, including comprehensive field force engagement with Primary Care Physicians, specialists and health systems delivering the right information at the right time.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: acquisitionBiohavenBiohaven stockbiopharmabiopharmaceuticalsbiotechcommon stockday tradingdow jones todayemerging growthhealth carehealth stocksinvestinginvesting newsinvestmentmedicalMergermicrocap stocksnewsNURTECPFEPFE stockPfizerpharmaceuticalspublic companysalessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtradingtreatmentwebull wallstreetbets
Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Twin Vee PowerCats NASDAQ VEEE Q2 2022 Financial Results Spotlight Growth

Twin Vee PowerCats (NASDAQ: VEEE) Releases Q2 2022 Results Showing 158% Increase in Revenue, Completes Spin-Off of Forza X1 (NASDAQ: FRZA)

August 12, 2022
Is Uber Technologies NYSE UBER Finally Investible Spotlight Growth

Is Uber (NYSE: UBER) Finally Investable?

August 11, 2022
Vacasa NASDAQ VCSA Q2 2022 Financial Results Spotlight Growth

Vacasa (NASDAQ: VCSA) Releases Second Quarter 2022 Financial Results Showing 31% Revenue Growth, Raises Full-Year 2022 Guidance After Strong Results

August 11, 2022
Allied Corp OTCQB ALID Shipment of Colombia Cannabis to Switzerland Spotlight Growth

Allied Corp (OTCQB: ALID) Successfully Ships 1728kgs of Colombian-Grown Commercial Cannabis Flower to Switzerland

August 11, 2022

Recent News

Twin Vee PowerCats NASDAQ VEEE Q2 2022 Financial Results Spotlight Growth

Twin Vee PowerCats (NASDAQ: VEEE) Releases Q2 2022 Results Showing 158% Increase in Revenue, Completes Spin-Off of Forza X1 (NASDAQ: FRZA)

August 12, 2022
Is Uber Technologies NYSE UBER Finally Investible Spotlight Growth

Is Uber (NYSE: UBER) Finally Investable?

August 11, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested